The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 73... ...
In addition to securing financial support for their research, medical scientists who study marijuana must demonstrate their compliance with a multitude of federal and state regulations before carrying out their investigations (see Chapter 11~. Thus, despite recent discoveries highlighted in Chapter 2, substantial clinical studies on the medicinal properties of marijuana remain scarce.
|
From page 74... ...
Although anxiety reduction may be a valuable form of treatment for some patients, it also interferes with attempts to determine whether THC relieves specific symptoms. Successful clinical trials must therefore eliminate this influence for example, by comparing the effect of THC on a particular symptom with that of a drug known to reduce anxiety but not the specific symptom being studied.
|
From page 75... ...
Weaker but still favorable scientific evidence supports the use of cannabinoids to treat muscle spasticity in patients with multiple sclerosis or spinal cord injury. The least promising indications discussed here include movement disorders, epilepsy, and glaucoma; nevertheless, animal experiments on movement disorders appear favorable enough to warrant continued exploration in the clinic.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.